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Crimean-Congo hemorrhagic fever (CCHF) virus (CCHFV; genus Nairovirus, family Bunyaviridae) 
causes severe disease in humans and circulates in many 
areas of Africa, Asia, and Europe. The disease is char-
acterized by a sudden onset of high fever, chills, severe 
headache, dizziness, and back and abdominal pains; addi-
tional signs and symptoms include nausea, vomiting, di-
arrhea, and neuropsychiatric and cardiovascular changes. 
In severe cases, hemorrhagic manifestations are present, 
ranging from petechiae to large areas of ecchymosis and 
bleeding from different sites of the body. Case-fatality rates 
range from 10% to 50% (1). Humans become infected with 
CCHFV through tick bites, mainly from Hyalomma spp. 
ticks, or by direct contact with blood or tissues from vi-
remic livestock or infected humans. The geographic range 
of CCHFV is the most extensive among tick-borne viruses 
related to human health, coinciding with the distribution of 
Hyalomma spp. ticks (1).
Greece is a country in the south of the Balkan Penin-
sula. Although sporadic cases or outbreaks of CCHF are 
often observed in other Balkan countries, including Bul-
garia, Albania, and Kosovo (2–5), only 1, fatal, CCHF case 
has been reported in Greece (6). The causative strain, Rho-
dopi-2008, clusters with other pathogenic Balkan CCHFV 
strains; however, it differs by >20% at the nucleotide level 
from the CCHFV strain AP92, which was isolated from 
Rhipicephalus bursa ticks collected in 1975 from goats in 
Vergina village in northern Greece (7). Human disease has 
not been associated with the AP92 strain, and only a few 
mild cases associated with an AP92-like strain have been 
reported in Turkey (8). 
Recent studies have shown that the seroprevalence 
of CCHFV antibodies (IgG) in the general population of 
Greece is ≈4%, but large differences are seen between re-
gions (range 0%–27%) (9–11). All of these studies used 
commercial ELISA kits to detect CCHFV IgG. Our aim 
was to retest these IgG-positive samples by using addition-
al serologic methods to evaluate the accuracy of the results 
of the earlier studies.
The Study
We investigated 118 serum samples that had shown 
positive test results for CCHFV IgG during 3 recent se-
roprevalence studies in Greece (9–11). The ages of the 
seropositive persons ranged from 26 to 90 years (median 
73 years). Oral consent had been given by all participants, 
and the seroprevalence studies were approved by the Ethics 
Committee of the Medical School of Aristotle University 
of Thessaloniki, Greece. For control, 20 CCHFV IgG– 
negative samples were tested. All positive samples had 
been tested by using a commercial ELISA (Vektor-Best, 
Novosibirsk, Russia) and stored at –70°C.
We tested all the samples by 3 methods: 1) an in-house, 
sandwich-capture ELISA described by the Ivanovsky Insti-
tute of Virology (Moscow, Russia), which uses inactivated 
sucrose-acetone–extracted whole-cell antigen of CCHFV 
strain UZ10145 prepared from the brain of infected new-
born white mice (12); 2) an in-house sandwich/indirect 
ELISA developed by the Centers for Disease Control and 
Prevention (Atlanta, GA, USA), which uses cells infected 
with CCHFV strain IbAr 10200 as the antigen (13); and 
3) a commercial immunofluorescence assay (IFA; CCHFV 
Mosaic 2, Euroimmun Medizinische Labordiagnostika 
AG, Lübeck, Germany), which uses cells transfected with 
CCHFV glycoprotein and nucleoprotein (CCHFV strain 
IbAr 10200) and control-transfected cells. Serum dilution 
of 1:100 was used in both ELISAs. IFA was performed ac-
cording to the manufacturer’s instructions by using 1:100 
serum dilution; when a negative result was obtained, the 
test was repeated at lower dilutions (1:40 and 1:16). In ad-
dition to these methods, we tested 48 of the 118 CCHFV 
IgG-positive samples by microneutralization assay using 
the CCHFV strain IbAr 10200; the samples selected for this 
test method were from all geographic regions of Greece 
(14). This procedure was performed in a high-containment 
Biosafety Level 4 laboratory at the Karolinska Institute 
(Stockholm, Sweden).
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ELISA results were noted as high-positive, positive, 
or low-positive according to the optical density in relation 
to the respective cutoff value. IFA grading was done on the 
basis of serum dilution: 1:16, low-positive; 1:40, positive; 
and >1:100, high-positive.
Both ELISAs and the IFA found CCHFV IgG in 116 
(98.3%) of 118 samples (Table). One sample was nega-
tive by all methods, including the neutralization test, and 
1 sample had positive results on 1 ELISA and showed a 
low-positive result by IFA (this sample was not tested by 
neutralization test). The microneutralization assay detected 
CCHFV in 47/48 samples tested; titers ranged from 10 to 
200 (mean 105). All IgG-negative samples had negative re-
sults by both ELISAs and by IFA.
Conclusions
Our results confirm previous findings that the CCHFV 
seroprevalence in Greece is high, especially in areas where 
livestock husbandry is a major occupation. All the methods 
used to test these samples produced similar results, which 
suggests that these methods are reliable laboratory tools for 
CCHFV seroprevalence studies. The commercial ELISA 
previously used had been used in various seroprevalence 
studies, including a study performed in response to a CCHF 
outbreak in western Afghanistan (15). That study reported 
(as unpublished data) that this kit had been previously com-
pared with an in-house ELISA from the US Army Medical 
Research Institute for Infectious Diseases (Fort Detrick, 
MD, USA), and results of the commercial and in-house 
ELISAs were comparable for all samples tested.
An advantage of the in-house ELISAs, which also run 
each sample with a negative antigen (background), is that 
they efficiently reduce the number of false-positive results. 
The commercial IFA includes control-transfected cells for 
the same reason. Furthermore, this IFA enables the detec-
tion of antibodies against CCHFV nucleoprotein or glyco-
protein antigens. The viral antigens in this specific IFA and 
in the applied in-house ELISAs are expressed in eukaryotic 
cells, which suggests that the glycosylation and 3D structure 
of the viral proteins were authentic in the assays we used.
Neutralization testing for CCHFV is a relatively diffi-
cult technique because the procedure must be performed in 
a Biosafety Level 4 environment and because nairoviruses 
produce weaker neutralizing antibody responses than do 
members of other Bunyaviridae family genera (1). In our 
study, CCHFV-neutralizing antibodies were detected in all 
but 1 of the samples tested.
Given that only 1 CCHF case has been reported in 
Greece, the high seroprevalence in specific regions might 
be related to a nonpathogenic or low-pathogenicity strain, 
such as the CCHFV strain AP92. The confirmation of 
the high CCHFV seroprevalence in specific areas of 
Greece needs further investigation to detect undiagnosed 
CCHF cases or elucidate the factors playing a role in sub-
clinical infections.
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